Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm

Jin Sook Yoon, Jae Chan Kim, Sang Yeul Lee, Jin Sook Yoon, Jae Chan Kim, Sang Yeul Lee

Abstract

Purpose: To compare the efficacies and safeties of Meditoxin (Medy-Tox, Korea) and Botox in the treatment of essential blepharospasm.

Methods: We performed a double-blind, randomized, comparative trial comparing Meditoxin and Botox for treatment of blepharospasm in 60 patients from the intention-to-treat (ITT) population and 52 patients from the per-protocol (PP) population. We analyzed the improvements in severity of spasm (SS) at four weeks post-injection as a primary efficacy outcome. Changes in eyelid closing force (CF) and functional visual status (FVS) after injection were analyzed for secondary efficacy outcomes, and adverse effects were demonstrated for the safety evaluation.

Results: Improvement in SS was noted in 90.3% of the Meditoxin group and 86.2% of the Botox group. There were no significant differences between treatment groups in the changes of CF and FVS post-injection (p>0.05). Since the lower limit of the 95% confidence interval (-1.76% for ITT, -1.64% for PP) was over the -15% threshold, we determined that Meditoxin was not inferior to Botox in either the ITT or PP populations. Adverse effects developed in 16.1% of the Meditoxin group and 27.6% of the Botox group, but no serious adverse events were found in either group.

Conclusions: Meditoxin and Botox were comparable in efficacy and safety in the treatment of essential blepharospasm.

Trial registration: ClinicalTrials.gov NCT00682760.

Keywords: Botox®; Essential blepharospasm; Meditoxin®.

Figures

Fig. 1
Fig. 1
Flow of patients throughout the trial. N, number of patients with data.
Fig. 2
Fig. 2
Distribution of severity of spasm scores (grade 0-4) before injection and at four weeks after injection in both Meditoxin® and Botox® treatment groups. M pre, Meditoxin® group before injection; M post, Meditoxin® group at four weeks post-injection; B pre, Botox® group before injection; B post, Botox® group at four weeks post-injection.

References

    1. Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347–350.
    1. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37:616–623.
    1. Taylor JD, Kraft SP, Kazdan MS, et al. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol. 1991;26:133–138.
    1. Park YC, Lim JK, Lee DK, Yi SD. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci. 1993;8:334–340.
    1. Elston JS. Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections. Br J Ophthalmol. 1987;71:664–668.
    1. Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can bedetected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1. Mov Disord. 1997;12:1013–1018.
    1. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235:197–199.
    1. Truong D, Comella C, Fernandez HH, et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14:407–414.
    1. Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–312.
    1. Rieder CR, Schestatsky P, Socal MP, et al. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm. Clin Neuropharmacol. 2007;30:39–42.
    1. Cakmur R, Ozturk V, Uzunel F, et al. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol. 2002;249:64–68.
    1. Stone AV, Ma J, Whitlock PW, et al. Effects of Botox and Neuronox on muscle force generation in mice. J Orthop Res. 2007;25:1658–1664.
    1. Khoo HM, Kim JC, Khoo BS. Treatment of blepharospasm and hemifacial spasm with Botulinum toxin A (Oculinum®) J Korean Ophthalmol Soc. 1990;31:59–68.
    1. Kim JC, Kim WS, Ahn SK, Shyn KH. Clinical studies in patients with essential blepharospasm and with hemifacial spasm. J Korean Ophthalmol Soc. 1991;32:837–843.
    1. Hatheway CH, Snyder JD, Seals JE, et al. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J Infect Dis. 1984;150:407–412.
    1. Cote TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407–415.
    1. Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008;115:585–591.
    1. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213–217.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する